Astellas Pharma Europe B.V.

Astellas employs over 3,000 people in Europe across sales and marketing, Research & Development (R&D) and manufacturing. The merger has enabled Astellas to strengthen its position in Europe. Astellas now has greater coverage of the European market, with 18 Sales and Marketing Affiliates, six plants and two R&D sites. Astellas Europe, hrough its International affiliates, is also responsible for the distribution of the company’s products in multiple markets in the Middle East, Africa and Latin America. Read details of Astellas’ European locations.

Research & Development

Astellas is focused on three key therapy areas: urology, dermatology, and transplantation. These therapy areas are key to Astellas Europe and the organisation is committed to continuing to explore opportunities and to develop new products which will better serve patients affected by conditions across these areas. Read more information about our work in these areas.
Astellas has global R&D facilities located in Japan, the US and Europe. The merger has resulted in greatly improved R&D capabilities with the total R&D budget for Astellas set at $1.3 billion. This will enable Astellas to accelerate the development of innovative and reliable products to solve patients’ unmet medical needs.
In Europe Astellas has two centres: Leiderdorp in the Netherlands which is the Headquarters of the R&D organisation and Munich in Germany which is focused on transplantation.
Astellas European R&D has a broad spectrum of departments covering a wide range of R&D disciplines including: Biological Development; Biometrics; Clinical Pharmacology Research; Clinical Research; Pharmaceutical Development; Pharmacovigilance; and Regulatory Affairs.
Whilst European R&D supports the three key areas of urology, dermatology and transplantation it is also involved in global research and development into diabetes, infectious diseases, gastrointestinal, central nervous system and inflammatory disorders. This includes leading the European arms of global clinical trial programmes.